Karyopharm Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Karyopharm Therapeutics Inc. (KPTI) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income-76.42-143.10-165.29-124.09-196.27
Depreciation & Amortization0.340.530.620.790.97
Stock Based Compensation18.4321.7135.4029.7824.41
Change in Working Capital-0.3031.42-19.99-23.191.36
Change in Accounts Receivable-3.8020.12-5.08-9.62-5.02
Change in Inventory-1.701.18-0.12-1.46-2.63
Change in Accounts Payable1.980.351.17-2.853.47
Change in Other Working Capital6.370.81-15.968.039.77
Other Operating Activities6.370.81-0.288.03-0.19
Net Cash from Operating Activities-127.49-92.72-149.55-107.12-160.23
Investing Activities
Capital Expenditures-0.140.00-0.12-5.71-0.15
Purchases of Investments-58.82-159.15-104.14-45.23-53.54
Sales/Maturities of Investments154.44167.09121.88192.780.00
Net Cash from Investing Activities95.477.94-104.26141.84-53.69
Financing Activities
Debt Repayment83.300.000.000.000.00
Common Stock Issued1.451.12193.749.90172.08
Other Financing Activities-43.110.000.0060.000.00
Net Cash from Financing Activities41.651.12193.7473.65172.08
Summary
Effect of Forex Changes on Cash-0.01-0.03-0.49-0.050.00
Net Change in Cash9.63-83.66-60.56108.37-41.57
Cash at Beginning of Period53.19136.89197.4589.120.00
Cash at End of Period62.8153.19136.89197.450.00
Free Cash Flow-127.63-92.72-149.67-112.83-160.38
Supplemental Disclosures
Interest Paid38.6021.2334.4515.5411.19